# A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia

> **NCT00250575** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 43 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Clozapine

## Key facts

- **NCT ID:** NCT00250575
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2016-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00250575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00250575, "A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00250575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*